Skip to main content
. 2016 May 19;6:26277. doi: 10.1038/srep26277

Figure 1. Bupivacaine alone and combined with anti-cancer drug decreased viability of both ovarian cancer (SKOV-3) and prostate cancer (PC-3) cells.

Figure 1

SKOV-3 and PC-3 cells were treated with bupivacaine (Bupi) from 1 μM to 1 mM for 24 or 72 h and cell survival was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (A) SKOV-3 cells with bupivacaine for 24 h. (B) SKOV-3 cells with bupivacaine for 72 h. (C) PC-3 cells with bupivacaine for 24 h. (D) PC-3 cells with bupivacaine for 72 h. (E) The viability of HK-2 cells treated with bupivacaine at 1 mM for 24 h. The viability of SKOV-3 (F) and PC-3 (G) were treated with bupivacaine (100 μM and 1 mM) plus anti-cancer drug taxol (100 nM) for 24 h. Data are presented as mean ± SD (n = 5). *P < 0.05; **P < 0.01; ***P < 0.001.